ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

selexipag

Also written as “Selexipag”, “selexipag (Uptravi)” and “Selexipag Film Coated Tablets (T1)”.

Its studies are mostly in Pulmonary Arterial Hypertension · Hypertension, Pulmonary · Hypertension · Scleroderma, Systemic · Sarcoidosis, led by 2 companies.

Drug pageSelexipag: every studyAll 25 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Mar 6, 201723 company-led studies, 3 open or runningNext primary completion: Jan 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson213 open or runningphase 4since Mar 6, 2017Apr 2, 2010Jan 31, 2027phase 3 · NCT05179876
Humanis Saglık Anonim Sirketiits history only20 open or runningphase 1since Apr 10, 2025Apr 10, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Johnson & Johnson only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Apr 2, 2010.

  1. Apr 18, 2016Phase 1 study in Healthy SubjectsNCT02745860 · 20 enrolled
  2. May 11, 2016Phase 1 study in Healthy SubjectsNCT02770222 · 40 enrolled
  3. Jun 2, 2016Phase 1 study in Healthy SubjectsNCT02791815 · 20 enrolled · France
  4. Aug 18, 2016Phase 1 study in Healthy SubjectsNCT02882425 · 19 enrolled
  5. Mar 6, 2017Phase 4 study in Pulmonary Arterial HypertensionNCT03078907 · 108 enrolled · United States, Austria, France and more
  6. Jun 9, 2017Phase 3 study in Pulmonary Arterial HypertensionNCT03187678 · 20 enrolled · United States, Germany
  7. Apr 3, 2018Phase 2 study in Pulmonary Arterial HypertensionNCT03492177 · 63 enrolled · United States, Belarus, Belgium and more
  8. Apr 6, 2018Phase 1 study in Healthy SubjectsNCT03496506 · 22 enrolled · Belgium
  9. Sep 27, 2018Phase 3 study in Chronic Thromboembolic Pulmonary HypertensionNCT03689244 · 128 enrolled · United States, Argentina, Australia and more
  10. May 7, 2019Phase 2 study in SarcoidosisNCT03942211 · 10 enrolled · United States, Belgium, Brazil and more
  11. Nov 8, 2019Phase 3 study in Hypertension, PulmonaryNCT04175600 · 138 enrolled · United States, Australia, Belarus and more
  12. Jun 15, 2020Phase 4 study in Pulmonary Arterial HypertensionNCT04435782 · 9 enrolled · United States, Argentina, Brazil and more
  13. Sep 22, 2020Phase 3 study in Hypertension, PulmonaryNCT04565990 · 43 enrolled · Belarus, India, Korea, Republic of and more
  14. Dec 17, 2021Phase 3 study in Hypertension, PulmonaryNCT05179876 · 280 planned · Belarus, Belgium, Bulgaria and more

Ahead

  1. Jan 31, 2027Primary completion: phase 3 study in Hypertension, PulmonaryNCT05179876

TargetBeta

PTGIR →read by rule
“Prostanoid IP receptor agonist”ChEMBL 37, by rule

Other programs on PTGIR

ProgramCompanyFurthest phaseStudies
treprostinilruleUnited Therapeuticsphase 473

Studies

All 21 Johnson & Johnson leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05179876Hypertension, Pulmonary · Belarus, Belgium, Bulgaria and more3RecruitingJan 31, 2027280
NCT04565990Hypertension, Pulmonary · Belarus, India, Korea, Republic of and more3CompletedNov 10, 202343
NCT04435782Pulmonary Arterial Hypertension · United States, Argentina, Brazil and more4TerminatedJul 28, 20239
NCT04175600Hypertension, Pulmonary · United States, Australia, Belarus and more3Active, not recruitingOct 11, 2024138
NCT03942211Sarcoidosis · United States, Belgium, Brazil and more2TerminatedApr 19, 202310
NCT03689244Chronic Thromboembolic Pulmonary Hypertension · United States, Argentina, Australia and more3TerminatedJun 7, 2022128
NCT03496506Healthy Subjects · Belgium1CompletedMay 10, 201822
NCT03492177Pulmonary Arterial Hypertension · United States, Belarus, Belgium and more2Active, not recruitingMar 28, 202263
NCT03187678Pulmonary Arterial Hypertension · United States, Germany3CompletedMay 29, 201820
NCT03078907Pulmonary Arterial Hypertension · United States, Austria, France and more4CompletedFeb 10, 2020108
NCT02882425Healthy Subjects1CompletedApr 201519
NCT02791815Healthy Subjects · France1CompletedSep 201620
NCT02770222Healthy Subjects1CompletedJul 201640
NCT02745860Healthy Subjects1CompletedJun 201620
NCT02558231Pulmonary Arterial Hypertension · United States, Australia, Austria and more3CompletedAug 29, 2019247
NCT02471183Pulmonary Arterial Hypertension · United States3CompletedDec 5, 201634
NCT02260557Scleroderma, Systemic · France, Germany, United Kingdom2CompletedApr 30, 201574
NCT02206295Bioequivalence1CompletedDec 201280
NCT02206204Cardiodynamics · United States1CompletedNov 2012159
NCT01112306Pulmonary Arterial Hypertension · United States, Argentina, Australia and more3CompletedAug 26, 2021709
NCT01106014Pulmonary Arterial Hypertension · United States, Argentina, Australia and more3CompletedApr 1, 20141,156

How it is read

Names in the registry

  • “Selexipag”, 13 entries
  • “selexipag”, 2 entries
  • “selexipag (Uptravi)”, 1 entry
  • “Selexipag Film Coated Tablets (T1)”, 1 entry
  • “Selexipag Film Coated Tablets (T2)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.